Sintilimab is a humanized IgG4 monoclonal antibody that binds to PD-1, targeting the interaction between PD-1 receptors and their ligands to block them, and effectively improves the function of T cells, enhancing immune surveillance and eliminating the ability of T cells in the tumor to produce the tumor immune response. This evidence concerns the gene PDCD1 and neoplasm.